Jane Osbourn

Jane has over 30 years of experience in biologics discovery and development. Most recently, she was Vice President for R&D and Site Leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology (CAT), where she contributed to the development of phage display technology.

Jane is a scientific leader in the field of antibody engineering and has made a significant contribution to the discovery and development of eight marketed drugs and over 40 clinical candidates. Jane is passionate about science education and the development of the UK biotech sector and served as Chair of the Board of Directors of the BioIndustry Association for four years before taking on a Corporate Board Member role earlier this year. She is currently a Director of Babraham Bioscience Technologies, and also a Director of Cambridge Enterprise. She was awarded Scrip’s Lifetime Achievement Award and an OBE in 2019 for services to drug discovery, development and biotechnology.